The role of non-covalent BTKis in the era of covalent BTKis for B-cell malignancies

(1:45)

BTKis in R/R MCL: overcoming resistance and the potential of combination regimens

(1:12)

The potential of BTKIs in multiple sclerosis

(3:31)

The MAHOGANY trial: emerging roles for BTKis in indolent lymphoma

(1:10)

The role of covalent and non-covalent BTKIs in the MCL treatment landscape

(2:38)

Updates on the use of BTKis in the treatment of MCL

(3:16)

Pericardial adverse events associated with BTKis in CLL: insights from two landmark trials

(1:12)

The real-world comparative effectiveness of covalent BTKis in R/R MCL

(2:)

Addressing cardiotoxicity associated with BTKis in patients with CLL

(3:19)

BTKis in WM: ibrutinib versus zanubrutinib and the use of non-covalent BTKis

(1:22)

Insights into the role of novel BTKis in the treatment landscape of R/R CLL

(2:49)

The real-world effectiveness of venetoclax-based therapy after BTKis in patients with CLL

(3:50)

BTK inhibitors: Investigating disease relevant mechanisms in multiple sclerosis

(3:51)

Adverse events associated with BTKis in the treatment of Waldenström’s macroglobulinemia

(1:27)

The potential role of non-covalent BTKis in mitigating covalent BTKi resistance

(1:24)

Infection risk associated with BTKIs in CLL: a meta-analysis of clinical trials

(58)

Next-generation covalent BTKis in the CLL treatment landscape

(2:18)

Managing adverse events associated with BTKis when treating patients with MCL

(1:22)

The role of covalent BTKis in the management of CLL

(2:16)

Targeting BTK to treat CLL: covalent versus non-covalent inhibitors

(1:30)